WAYNE, Pa., Nov. 13 /PRNewswire/ -- At a time when industry retrenchment, lay-offs and even bail outs dominate the news, a specialty pharmaceutical company located outside Philadelphia is experiencing growth. This week, FemmePharma Global Healthcare, Inc announces the establishment of a new division, FemmePharma Mental Healthcare, Central Nervous System, that will focus on central nervous system (CNS) disorders in women.
"We are energized to expand our commitment in women's health even at a time when the pharmaceutical industry is retreating in this area," says FemmePharma's President and CEO Gerianne Tringali DiPiano. "For FemmePharma, these are times which provide a wealth of opportunities in women's health."
Since its establishment in 1996, FemmePharma has focused on women's gynecological health issues, including urinary incontinence and fibrocystic breast disease. With its expansion into CNS, that focus is growing to develop treatments particularly for depression (including postpartum depression), anxiety disorders, eating disorders and neuropathic pain specific to women.
"We know that women respond differently than men to medications for depression," Tringali DiPiano says, referring to a study published in 2006 in the Journal of Affective Disorders. "And this is just one example. Understanding and developing treatments that respond to women's unique health challenges is FemmePharma's mission so our expansion into CNS disorders in women represents a natural progression," Tringali DiPiano says.
While FemmePharma continues to invest and grow, the pharmaceutical industry in general is withdrawing. In April of this year, a Wall Street Journal website estimated that as many as 25,000 pharmaceutical jobs were expected to be eliminated in 2008. And in October, Wyeth announced that it would eliminate discovery work in women's health while reducing its therapeutic areas from 14 to six.
Tringali DiPiano says this represents a concern for her personally while providing an exciting opportunity for her company.
"The gap in developing treatments unique to women is widening even though there are significant unmet needs," Tringali DiPiano says. "Without question our expansion into CNS is an indication of our continued growth and commitment to women and their unique health needs."
The women's health sector represents an estimated $116 billion market by the year 2010, according to a report by Research and Markets.com.
|SOURCE FemmePharma Global Healthcare, Inc|
Copyright©2008 PR Newswire.
All rights reserved